Meeting
2019 ASCO Annual Meeting
ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Authors
Peter Hillmen
St. James's University Hospital, Leeds, United Kingdom
Peter Hillmen , Jennifer R. Brown , John C. Byrd , Barbara Eichhorst , Nicole Lamanna , Susan Mary O'Brien , Lugui Qiu , Jason C. Paik , James D. Hilger , Jane Huang , Constantine S. Tam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03734016
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7572)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7572
Abstract #
TPS7572
Poster Bd #
323a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2018 ASCO Annual Meeting
Phase 3 zanubrutinib (BGB‑3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
First Author: Peter Hillmen
Poster
2018 ASCO Annual Meeting
ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.
First Author: Michael Wang
Poster
2024 ASCO Annual Meeting
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.
First Author: Mazyar Shadman